FiercePharmaAsia—J&J-Hanmi obesity breakup; BI-Yuhan NASH tie-up; GSK sites in China, Singapore

Asia Map
Hanmi Pharma, Yuhan, GlaxoSmithKline and Takeda made our news this week. (Google)

After the July Fourth holiday, we've got two weeks of biopharma movement from Asia to catch up on. South Korea's Hanmi Pharmaceutical is looking at a loss of up to $810 million in milestones after Johnson & Johnson ditched its obesity collaboration. Meanwhile, fellow Korean drugmaker Yuhan has teamed up with Boehringer Ingelheim on a nonalcoholic steatohepatitis (NASH) deal that could be worth $870 million. Following a decision made in 2017, GlaxoSmithKline has sold a production site in Chinaalong with rights to antiviral drug lamivudineto a Fosun Pharma unit, just as it opens new manufacturing facilities worth $95 million in Singapore.

1. J&J dumps Hanmi obesity drug following midphase trials

Hanmi Pharmaceutical’s stock plummeted nearly 30% last week following news that Johnson & Johnson had returned the rights of diabetes candidate HM12525A. In two phase 2 trials, the drug met the primary endpoint of weight reduction, but blood glucose control failed J&J’s expectation, Hanmi said. It marked another serious blow for the South Korean company after it lost a BTK inhibitor deal with Eli Lilly in January and one over cancer drug olmutinib with Boehringer Ingelheim in 2016.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

2. Boehringer grabs Yuhan's NASH prospect in $870M biobucks deal

Fellow South Korean firm Yuhan is in for a win. After forming a $785 million pact with Gilead Sciences over two NASH drugs in January, it has attracted the interest of Boehringer. The German pharma is picking up a dual agonist of GLP-1 and FGF21 also for NASH, paying Yuhan $40 million upfront and promising up to $830 million in milestone payments.

3. Fosun Pharma picks up GSK plant in China along with rights to make Epivir generic

GSK opens $95M continuous production operation in Singapore

GlaxoSmithKline has opened new facilities worth about $95 million at its Jurong site in Singapore. One of two new continuous manufacturing facilities will produce APIs for clinical trials, and an expanded building will make APIs for HIV medicines including its key drug Tivicay. At the same time, the British drugmaker has reached a deal to sell its Suzhou factory in China to Fosun Pharma for about $36 million. The sale also includes rights to antiviral drug lamivudine.

4. Post-Shire buy, Takeda investors want executives to return pay if performance lags

At Takeda Pharmaceutical’s recent general meeting, the majority of shareholders backed a proposal that would allow Takeda to claw back executive pay should its Shire deal not live up to expectations, though the clause fell short of the two-thirds majority needed to move through. Influential proxy advisers Institutional Shareholder Services and Glass Lewis previously both supported the proposal.

5. Aurobindo gets warning letter over valsartan recall mess

In a warning letter, the FDA lambasted an Aurobindo Pharma plant for using solvents to produce drugs that led to potentially cancer-causing impurities. The letter didn’t call out heart drug valsartan, but the inspection came just weeks after Aurobindo recalled 80 lots of valsartan due to the impurities, and the FDA previously determined that the possible carcinogens can come from processes that use certain solvents.

6. With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger

After a two-week inspection, the FDA has once again cited Biocon’s facilities where it will make its Mylan-partnered challenger to Sanofi’s Lantus. The Indian company said it would respond to the Form 483 soon and that the warning wouldn't affect commercialization plans for the product in the U.S.

7. Eisai launches first startup incubator under its genomics center for dementia

Eisai opened its first startup incubator as part of its Cambridge, Massachusetts-based center. Rather than looking at the amyloid beta and tau targets for dementia, the center is focused on modulating the body’s immune mechanism to treat dementia by employing genomics research, data science and precision chemistry.

8. China's biotech cash injection suddenly drops as U.S. scrutiny intensifies: report

As the U.S.-China trade spat drags on and as the U.S. has put increasing scrutiny on foreign investments in U.S. high-tech businesses, Chinese cash injection into U.S. biotech has nosedived. In the first six months, Chinese VC funds for U.S. biotech firms dropped to $725 million from $1.65 billion in the same period last year, according to PitchBook.

9. U.S. looks to extradite Chinese researcher in GSK trade secrets case: Reuters

The U.S. wants Switzerland to hand over a Chinese scientist accused of helping his sister steal trade secrets from GSK, Reuters reported. The sister, a former GSK employee, pleaded guilty last August to attempting to steal confidential research. Gongda Xue, the brother, allegedly received those secrets, conducted tests at his workplace in Basel and sent the results to associates in China. 

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.